Jan 14, 2021 / 10:20PM GMT
Ron Cohen - Acorda Therapeutics, Inc. - Founder, CEO, President & Director
Good afternoon, everyone. I'm Ron Cohen. I'm President and CEO of Acorda Therapeutics, and thank you for joining us for an update on the company. And thanks to JPMorgan for having us.
Without further ado, first, I want to just remind you all that the presentation does contain forward-looking statements, and we encourage you to consult our more complete filings with the SEC.
Just overview of Acorda Therapeutics. Our mission is to develop therapies that restore function and improve the lives of people with neurological disorders. So far, we have developed and achieved approval and brought to market 2 significant therapies: one, INBRIJA for people with OFF periods with Parkinson's disease; and AMPYRA for improving walking, a vital function in people with multiple sclerosis.
Moving to Slide 4, we are going to look first at our 2020 goal achievement.
And on Slide 5, those goals, which we achieved in full were: first, to monetize the excess capacity at our manufacturing facility; that to improve
Acorda Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers